Resource Summary Report

Generated by dkNET on Sep 2, 2026

HCC1419

RRID:CVCL_1251
Type: Cell Line

Proper Citation

RRID:CVCL_1251

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1251

Proper Citation: RRID:CVCL_1251

Description: Cell line HCC1419 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast ductal carcinoma

Defining Citation: PMID:9833771, PMID:9865903, PMID:11314036, PMID:19582160, PMID:22460905, PMID:22585861, PMID:23601657, PMID:24176112, PMID:25485619, PMID:25877200, PMID:25960936, PMID:26589293, PMID:27397505, PMID:28196595, PMID:30894373, PMID:31068700, PMID:35839778

Comments: Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC1419

Synonyms: HCC-1419, Hamon Cancer Center 1419

Cross References: CLO:CLO_0003636, EFO:EFO_0005372, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2326, BioGRID_ORCS_Cell_line:665, BioSample:SAMN03471438, BioSample:SAMN10988522, cancercelllines:CVCL_1251,

Cell_Model_Passport:SIDM00882, ChEMBL-Cells:CHEMBL3308738, ChEMBL-Targets:CHEMBL1075455, Cosmic:687475, Cosmic:904363, Cosmic:907045, Cosmic:1287884, Cosmic:1308992, Cosmic:1603201, Cosmic:1935005, Cosmic:2165005, Cosmic-CLP:907045, DepMap:ACH-000277, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:907045, GEO:GSM149984, GEO:GSM149992, GEO:GSM150000, GEO:GSM186716, GEO:GSM186717, GEO:GSM217573, GEO:GSM219874, GEO:GSM274661, GEO:GSM344371, GEO:GSM344421, GEO:GSM350553, GEO:GSM378145, GEO:GSM459729, GEO:GSM783940, GEO:GSM844544, GEO:GSM847322, GEO:GSM887038, GEO:GSM888108, GEO:GSM984231, GEO:GSM1053722, GEO:GSM1172864, GEO:GSM1374498, GEO:GSM1421430, GEO:GSM1669844, IARC_TP53:21361, IARC_TP53:22811, IARC_TP53:30202, KCLB:9S1419, LiGeA:CCLE_174, LINCS_HMS:50207, LINCS_LDP:LCL-1314, PharmacoDB:HCC1419_474_2019, PRIDE:PXD030304, Progenetix:CVCL_1251, PubChem_Cell_line:CVCL_1251, SLKBase:3514, Wikidata:Q54881567

ID: CVCL_1251

Record Creation Time: 20220427T220317+0000

Record Last Update: 20260829T233631+0000

Ratings and Alerts

No rating or validation information has been found for HCC1419.

No alerts have been found for HCC1419.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 128 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. Cancer discovery, 16(1), 81.

Pequerul R, et al. (2025) Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors. Cell chemical biology.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. Cell reports. Medicine, 6(12), 102478.

Duan L, et al. (2025) Coinhibition of Aurora Kinase B and SUV4-20H Induces Synthetic Lethality in Wild-type p53-Deficient Cancer Cells. Molecular cancer therapeutics, 24(7),

1020.

Ishibashi K, et al. (2024) Astrocyte-induced mGluR1 activates human lung cancer brain metastasis via glutamate-dependent stabilization of EGFR. Developmental cell, 59(5), 579.

Moyer CL, et al. (2024) IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(11), 2558.

Hlavaty SI, et al. (2024) ACSS1-dependent acetate utilization rewires mitochondrial metabolism to support AML and melanoma tumor growth and metastasis. Cell reports, 43(12), 114988.

Moon SJ, et al. (2023) CTTN Overexpression Confers Cancer Stem Cell-like Properties and Trastuzumab Resistance via DKK-1/WNT Signaling in HER2 Positive Breast Cancer. Cancers, 15(4).

Wei L, et al. (2023) Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor-Positive Breast Cancer. Cancer research, 83(3), 456.

Liu S, et al. (2023) Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Breast cancer research : BCR, 25(1), 62.

Kim TW, et al. (2023) Nodakenin Induces ROS-Dependent Apoptotic Cell Death and ER Stress in Radioresistant Breast Cancer. Antioxidants (Basel, Switzerland), 12(2).

Weisser NE, et al. (2023) An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nature communications, 14(1), 1394.

Costantini S, et al. (2022) An Integrated In Silico, In Vitro and Tumor Tissues Study Identified Selenoprotein S (SELENOS) and Valosin-Containing Protein (VCP/p97) as Novel Potential Associated Prognostic Biomarkers in Triple Negative Breast Cancer. Cancers, 14(3).

Rivas EI, et al. (2022) Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors. Nature communications, 13(1), 5310.

Wang B, et al. (2022) A miR-34a-guided, tRNAiMet-derived, piR_019752-like fragment (tRiMetF31) suppresses migration and angiogenesis of breast cancer cells via targeting PFKFB3. Cell death discovery, 8(1), 355.

Schuster C, et al. (2022) Combinatorial Effects of the Natural Products Arctigenin, Chlorogenic Acid, and Cinnamaldehyde Commit Oxidation Assassination on Breast Cancer Cells. Antioxidants (Basel, Switzerland), 11(3).

Gutierrez DA, et al. (2022) Identification of a Potent Cytotoxic Pyrazole with Anti-Breast Cancer Activity That Alters Multiple Pathways. Cells, 11(2).

Liu M, et al. (2022) INHBA is a mediator of aggressive tumor behavior in HER2+???basal breast cancer. Breast cancer research : BCR, 24(1), 18.

Flint AL, et al. (2022) Modified Curcumins as Potential Drug Candidates for Breast Cancer: An Overview. Molecules (Basel, Switzerland), 27(24).

Gu Y, et al. (2022) TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer. Oncogene, 41(35), 4119.